Literature DB >> 22739694

Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

G F Machado-de-Assis1, A R Silva, V A L Do Bem, M T Bahia, O A Martins-Filho, J C P Dias, P Albajar-Viñas, R M Torres, M Lana.   

Abstract

We performed a critical study of conventional serology, followed by supplementary serological, parasitological, and molecular tests, to assess the response to etiologic treatment of Chagas' disease. A group of 94 Chagas' disease patients treated with benznidazole at least 10 years earlier were evaluated from the laboratory and clinical points of view. When conventional serology (enzyme-linked immunosorbent assay [ELISA], indirect immunofluorescence [IIF], and indirect hemagglutination [IHA]) and classic criteria (consistent results with any two of the three tests) or more rigorous criteria (consistent results from the three tests) were used, 10.6% and 8.5% of patients were considered treated and cured (TC) by classic and rigorous criteria, respectively. Patients were then evaluated using supplementary (recombinant ELISA and Trypanosoma cruzi excreted-secreted antigen blotting [TESA-blot]), parasitological (hemoculture), and molecular (PCR) tests. The results of recombinant ELISA were similar to those with the rigorous criterion (three consistent test results). The TESA-blot group showed a higher percentage (21.3%) of negative results than the groups defined by either cure criterion. Hemoculture and PCR gave negative results for all treated and cured (TC) patients, regardless of the criterion used. Recombinant ELISA and TESA-blot tests showed negative results for 70% and 87.5% of the patients categorized as TC by the classic and three-test criteria, respectively. For patients with discordant conventional serology, the supplementary serological and molecular tests were the decisive factor in determining therapeutic failure. Clinical evaluation showed that 62.5% of TC patients presented with the indeterminate form of the disease. Additionally, treated patients with negative TESA-blot results should be reevaluated later with all methodologies used here to verify whether TESA-blot is a reliable way to determine early parasitological cure of Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739694      PMCID: PMC3416099          DOI: 10.1128/CVI.00274-12

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  50 in total

1.  Chagas' disease diagnosis: comparative analysis of parasitologic, molecular, and serologic methods.

Authors:  M L Gomes; L M Galvao; A M Macedo; S D Pena; E Chiari
Journal:  Am J Trop Med Hyg       Date:  1999-02       Impact factor: 2.345

2.  Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood.

Authors:  M L Gomes; A M Macedo; A R Vago; S D Pena; L M Galvão; E Chiari
Journal:  Exp Parasitol       Date:  1998-01       Impact factor: 2.011

3.  Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America.

Authors:  E S Umezawa; S F Bastos; M E Camargo; L M Yamauchi; M R Santos; A Gonzalez; B Zingales; M J Levin; O Sousa; R Rangel-Aldao; J F da Silveira
Journal:  J Clin Microbiol       Date:  1999-05       Impact factor: 5.948

4.  [Hemoculture: sensitive technique in the detection of Trypanosoma cruzi in chagasic patients in the chronic phase of Chagas disease].

Authors:  Z M Luz; M G Coutinho; J R Cançado; A U Krettli
Journal:  Rev Soc Bras Med Trop       Date:  1994 Jul-Sep       Impact factor: 1.581

5.  Immunoblot assay using excreted-secreted antigens of Trypanosoma cruzi in serodiagnosis of congenital, acute, and chronic Chagas' disease.

Authors:  E S Umezawa; M S Nascimento; N Kesper; J R Coura; J Borges-Pereira; A C Junqueira; M E Camargo
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

6.  Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection.

Authors:  A L de Andrade; F Zicker; R M de Oliveira; S Almeida Silva; A Luquetti; L R Travassos; I C Almeida; S S de Andrade; J G de Andrade; C M Martelli
Journal:  Lancet       Date:  1996-11-23       Impact factor: 79.321

7.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

8.  Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up.

Authors:  R Viotti; C Vigliano; H Armenti; E Segura
Journal:  Am Heart J       Date:  1994-01       Impact factor: 4.749

9.  Flow cytometry, a new approach to detect anti-live trypomastigote antibodies and monitor the efficacy of specific treatment in human Chagas' disease.

Authors:  O A Martins-Filho; M E Pereira; J F Carvalho; J R Cançado; Z Brener
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

10.  Treatment of congenital Chagas' disease diagnosed and followed up by the polymerase chain reaction.

Authors:  G Russomando; M M de Tomassone; I de Guillen; N Acosta; N Vera; M Almiron; N Candia; M F Calcena; A Figueredo
Journal:  Am J Trop Med Hyg       Date:  1998-09       Impact factor: 2.345

View more
  13 in total

1.  Success of benznidazole chemotherapy in chronic Trypanosoma cruzi-infected patients with a sustained negative PCR result.

Authors:  L Murcia; B Carrilero; F Ferrer; M Roig; F Franco; M Segovia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-04       Impact factor: 3.267

2.  Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods.

Authors:  Catalina Muñoz; Inés Zulantay; Werner Apt; Sylvia Ortiz; Alejandro G Schijman; Margarita Bisio; Valentina Ferrada; Cinthya Herrera; Gabriela Martínez; Aldo Solari
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

Review 3.  Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps.

Authors:  V Balouz; F Agüero; C A Buscaglia
Journal:  Adv Parasitol       Date:  2016-11-14       Impact factor: 3.870

4.  The Trypomastigote Small Surface Antigen from Trypanosoma cruzi Improves Treatment Evaluation and Diagnosis in Pediatric Chagas Disease.

Authors:  Virginia Balouz; Luciano J Melli; Romina Volcovich; Guillermo Moscatelli; Samanta Moroni; Nicolás González; Griselda Ballering; Margarita Bisio; Andrés E Ciocchini; Carlos A Buscaglia; Jaime Altcheh
Journal:  J Clin Microbiol       Date:  2017-10-04       Impact factor: 5.948

5.  Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).

Authors:  Maite Vallejo; Pedro Pa Reyes; Mireya Martinez Garcia; Alejandro G Gonzalez Garay
Journal:  Cochrane Database Syst Rev       Date:  2020-12-11

Review 6.  Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.

Authors:  Yanina Sguassero; Cristina B Cuesta; Karen N Roberts; Elizabeth Hicks; Daniel Comandé; Agustín Ciapponi; Sergio Sosa-Estani
Journal:  PLoS One       Date:  2015-10-05       Impact factor: 3.240

Review 7.  Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives.

Authors:  Maria-Jesus Pinazo; Maria-Carmen Thomas; Juan Bustamante; Igor Correia de Almeida; Manuel-Carlos Lopez; Joaquim Gascon
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-28       Impact factor: 2.743

8.  Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.

Authors:  Jaquelline Carla Valamiel de Oliveira-Silva; Girley Francisco Machado-de-Assis; Maykon Tavares Oliveira; Nívia Carolina Noguieira Paiva; Márcio Sobreira Silva Araújo; Cláudia Martins Carneiro; Olindo Assis Martins-Filho; Helen Rodrigues Martins; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-01-23       Impact factor: 2.743

9.  Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment.

Authors:  Cynthia Santamaria; Eric Chatelain; Yves Jackson; Qianqian Miao; Brian J Ward; François Chappuis; Momar Ndao
Journal:  BMC Infect Dis       Date:  2014-06-03       Impact factor: 3.090

Review 10.  Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?

Authors:  Marta de Lana; Olindo Assis Martins-Filho
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.